Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

M.Video-Eldorado in July-August increased turnover by 40%

9/11/23 MVID

Rostelecom-Solar will divide the business to get away from the image of a state-owned company

9/11/23 RTKM

Samolet will build Far Eastern Quarter in Korsakov

9/11/23 SMLT

Sistema plans to resume IPOs of non-public assets in 2024

9/11/23 AFKS

Sollers expects to reach the production volume of 10 thousand pickup trucks

9/11/23 SVAV

VTB needs a trillion in capital over the next five years

9/11/23 VTBR

En+ Group wants to build a wind power plant to export energy to China

9/11/23 ENPG

Gazprom launched the first lines at the Amur GPP

9/11/23 GAZP

Sberbank reported for 8 months of 2023 by RAS

9/11/23 SBER

MD Medical reported for 6 months of 2023

9/11/23 MDMG